Nova: Welcome to Aibrary. I'm Nova, and today we're diving into a book that couldn't be more timely. Picture this: over 40% of American adults are living with obesity, and in 2024 alone, more than one in four adults with diabetes turned to a single class of medications — GLP-1s — to help manage their condition. We're talking about drugs that have been called the biggest breakthrough in metabolic health in a generation. Ozempic, Wegovy, Mounjaro, Zepbound — these names are everywhere now, from pharmacy shelves to social media feeds to dinner party conversations.

Nova: : And I have to admit, Nova, every time I hear another celebrity or influencer casually mention they're on one of these, I wonder — is this really the miracle everyone says it is? Or is there a lot more going on beneath the surface?

Nova: That's exactly the question that Jeremy Kahn sets out to answer in The Ultimate Guide to the New GLP-1 Medications for Weight Loss and Diabetes. This is not a quick-fix manifesto. Kahn takes readers methodically through the science, the history, the evidence, the risks, the costs, and the future of these drugs. He's asking the big question: what happens when a society gets access to medications that can fundamentally alter appetite and body weight?

Nova: : That's a profound framing. Because we're not just talking about a new diet pill here.

Nova: Exactly. By the end of today's episode, you'll understand how these drugs actually work in the body, why some are more effective than others, what the side effect landscape really looks like, why access remains so uneven, and where the science is headed next. Let's get into it.

Nova: So let's start where Kahn starts — with what's happening inside your body. GLP-1 stands for glucagon-like peptide-1. It's a hormone your gut naturally releases after you eat. Its main job is to tell your pancreas, hey, food is coming, release some insulin. But it does a lot more than that.

Nova: : Okay, so it's a natural signaling molecule. But if our bodies already make it, why do we need a drug version?

Nova: Great question. The GLP-1 your body produces naturally only lasts about two minutes in your bloodstream before it gets broken down by an enzyme called DPP-4. Kahn explains this beautifully — it's like your body is constantly shredding the message before it can be fully read. The medications bypass this. They're engineered to resist that enzyme, so they stick around for days instead of minutes. That means the signal gets amplified dramatically.

Nova: : So you're getting a much louder and longer version of a message your body was already trying to send. What does that amplified message actually do?

Nova: Several things simultaneously. First, it stimulates insulin secretion when blood sugar is high — but crucially, not when it's normal, which is why these drugs carry a very low risk of hypoglycemia. Second, it suppresses glucagon, the hormone that tells your liver to dump glucose into your blood. Third, and this is the part everyone talks about, it slows gastric emptying. Food sits in your stomach longer, so you feel full faster and stay full longer.

Nova: : That explains the appetite suppression piece. But Kahn also talks about something happening in the brain, right?

Nova: Yes, and this might be the most fascinating part. GLP-1 receptors exist in several brain regions, including the hypothalamus and the brainstem. When activated, they directly reduce appetite and food intake. Kahn cites research showing these drugs may also modulate reward pathways — meaning that slice of cake or bag of chips becomes genuinely less compelling. It's not just willpower; it's a neurobiological shift. Some researchers even describe it as quieting what they call food noise — that constant, intrusive thinking about eating.

Nova: : Food noise. That's such a powerful concept. I think a lot of people listening right now are nodding because they know exactly what that feels like.

Nova: And that's a huge part of why these drugs feel revolutionary. Kahn emphasizes that for the first time, we have medications that address the underlying biology of obesity rather than just telling people to eat less and move more. As one researcher quoted in the book puts it, we spent decades treating obesity as a character flaw when it was largely a biological condition.

Nova: Kahn dedicates a major section of the book to mapping out the available medications, because honestly, the naming conventions alone are confusing enough to make your head spin. So let's break it down. On the semaglutide side, you have Ozempic, which is FDA-approved for type 2 diabetes, and Wegovy, which is the exact same molecule but approved specifically for chronic weight management.

Nova: : So same drug, different branding and dosing?

Nova: Precisely. Semaglutide is a GLP-1 receptor agonist — it mimics the natural GLP-1 hormone. Then you have tirzepatide, which is sold as Mounjaro for diabetes and Zepbound for weight loss. Tirzepatide is what's called a dual agonist — it activates both GLP-1 receptors and GIP receptors. GIP is another gut hormone, glucose-dependent insulinotropic polypeptide, that also influences metabolism.

Nova: : So tirzepatide is basically hitting two targets instead of one. Does that make it more effective?

Nova: That's exactly what the evidence suggests, and Kahn walks through the data carefully. He references a major study published in JAMA Internal Medicine that compared semaglutide and tirzepatide head-to-head for weight loss. Both drugs produced substantial weight reduction, but tirzepatide came out ahead. In clinical trials, people on the highest dose of tirzepatide lost, on average, more than 20% of their body weight. Semaglutide at its highest dose produced about 15% weight loss on average.

Nova: : Fifteen to twenty percent of body weight — those are numbers we used to associate only with bariatric surgery.

Nova: That's the comparison Kahn draws repeatedly. We're now in territory that rivals surgical interventions. But he's also careful to contextualize — these are averages from clinical trials with structured support. Real-world results vary considerably. And he makes the point that these drugs are meant to be taken long-term. In studies where people stopped taking semaglutide, they regained, on average, two-thirds of the lost weight within a year.

Nova: : That's sobering. So it's not a cure — it's an ongoing treatment.

Nova: Exactly. Kahn frames it like managing blood pressure or cholesterol. You wouldn't take a statin for six months and expect your cholesterol to stay low forever. The same principle applies here. He also discusses the other GLP-1 drugs on the market — liraglutide, sold as Victoza and Saxenda, and dulaglutide, sold as Trulicity. These are the older generation and produce more modest weight loss, but they're still valuable tools, especially for diabetes management. And then there's the newest development: oral semaglutide, a daily pill form that was recently approved for weight loss, which Kahn sees as potentially expanding access significantly.

Nova: No honest guide to these medications would be complete without a frank discussion of side effects, and Kahn doesn't shy away from this. The most common ones are gastrointestinal — nausea, vomiting, diarrhea, constipation. In clinical trials, GI side effects occurred in a significant minority of patients, and they tend to be worst during dose escalation.

Nova: : That's the part I hear about most from people actually taking these drugs. Some say the nausea is really rough, especially at first. How does Kahn suggest managing that?

Nova: He devotes a whole chapter to practical management strategies. Key recommendations include eating smaller, more frequent meals, avoiding high-fat and fried foods, staying well hydrated, and most importantly, following the prescribed dose escalation schedule rather than rushing to higher doses. The body needs time to adapt. He also notes that for most people, these side effects diminish over time and are manageable with these strategies.

Nova: : And what about the scarier stuff? I've seen headlines about pancreatitis, gallbladder issues, even thyroid cancer warnings.

Nova: Kahn takes these seriously and presents the evidence transparently. The FDA requires a boxed warning for thyroid C-cell tumors based on rodent studies — but he notes that this risk has not been confirmed in humans, and the relevance to people remains uncertain. Still, people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not take these drugs. There is also a slightly elevated risk of pancreatitis and gallbladder disease, including gallstones, likely related to rapid weight loss itself. Kahn's advice is straightforward: know the warning signs, and don't ignore persistent severe abdominal pain.

Nova: : So these are real risks but relatively rare, and the key is being informed and working with a doctor who knows what to watch for.

Nova: That's the balance Kahn strikes throughout the book. He also addresses a concern that has gotten a lot of attention recently — muscle loss. When you lose weight rapidly, some of what you lose is lean mass, not just fat. Kahn emphasizes that resistance training and adequate protein intake are non-negotiable companions to GLP-1 therapy. He quotes several clinicians who say prescribing these medications without also prescribing exercise and nutrition guidance is a mistake.

Nova: : That feels like such an important point. Because if someone loses a lot of weight but also loses significant muscle mass, their metabolism could actually slow down, making it even harder to maintain results.

Nova: Exactly. And Kahn explores another fascinating phenomenon — what some clinicians call GLP-1 face, the hollowed-out facial appearance that can occur with rapid weight loss. It's essentially the same effect that happens with any significant weight loss, but the speed makes it more noticeable. These are the kinds of nuanced, practical details that make Kahn's guide valuable — he's not selling a miracle, he's preparing people for the full experience.

Nova: Let's talk about the elephant in the room — and it's an expensive elephant. Wegovy and Zepbound list at over a thousand dollars per month without insurance. Kahn's book dedicates significant space to the access crisis these price tags create.

Nova: : Over a thousand dollars a month. For a medication you're supposed to take indefinitely. That's just not feasible for most people.

Nova: It's not. And Kahn lays out the numbers starkly. According to the CDC data he cites, about 26.5% of adults with diagnosed diabetes were using GLP-1 injectables by 2024. Among adults aged 50 to 64, that number jumps to 33.3%. Usage was most common among those with higher BMIs. But those statistics mask enormous disparities. Employer-sponsored insurance plans are increasingly restricting coverage or imposing high co-pays. Medicare is prohibited by law from covering medications for weight loss alone, though it can cover them for diabetes. And as of the data Kahn reviews, only about 13 state Medicaid programs cover GLP-1s for obesity treatment.

Nova: : So we have this incredible medical breakthrough, and large swaths of the population simply can't access it. That feels deeply wrong.

Nova: Kahn devotes an entire chapter to this ethical tension. He also dives into the rise of compounded versions — essentially pharmacy-mixed alternatives that emerged during the FDA-declared shortages. The FDA has since cracked down, removing tirzepatide from the shortage list in October 2024 and semaglutide in early 2025, which means compounding pharmacies were no longer permitted to produce copies. Kahn also warns about the dangers of unregulated products — including semaglutide salts sold online that are not the same as the FDA-approved medications.

Nova: : I've seen those ads on social media. It's the wild west out there.

Nova: It really is. And Kahn makes an important argument: the demand for these drugs is exposing fundamental flaws in how we price and distribute medications. He notes that in countries with national health systems and price negotiations, these drugs cost a fraction of what they do in the United States. The book is as much a policy critique as it is a medical guide.

Nova: : So Kahn is essentially saying: the science is remarkable, but our systems for delivering it are broken.

Nova: That's the core of his argument. And he suggests that the coming wave of new competition — more drugs, more manufacturers, potentially oral versions that are cheaper to produce — could reshape this landscape. But he stops short of predicting how quickly or fairly that will happen.

Nova: One of the most compelling sections of Kahn's book explores what researchers are discovering about GLP-1 medications beyond diabetes and weight loss. The benefits appear to extend into areas nobody initially expected.

Nova: : I've heard murmurings about this — heart health, maybe? But it sounds almost too good to be true.

Nova: The evidence keeps piling up. Kahn details the SELECT trial, which showed that semaglutide reduced the risk of major cardiovascular events — heart attacks, strokes, cardiovascular death — by 20% in people with established cardiovascular disease who were overweight or obese, independent of blood sugar control. That's a big deal. The FDA expanded Wegovy's label to include cardiovascular risk reduction based on this data.

Nova: : Twenty percent reduction in heart attacks and strokes. That's not a weight loss drug anymore. That's a cardiovascular drug that also causes weight loss.

Nova: That's exactly the reframing Kahn encourages. He also covers the emerging evidence on kidney protection. Studies have shown GLP-1s can slow the progression of kidney disease in people with type 2 diabetes. The WHO, in its landmark December 2025 global guideline, specifically highlighted these cardiorenal benefits as part of its recommendation framework.

Nova: : And there's been research on addiction, right? Alcohol, maybe even other substances?

Nova: Yes, and Kahn treats this area with appropriate caution. There are intriguing signals — anecdotal reports from patients who say their desire for alcohol diminished significantly on these medications, and some preclinical research suggesting GLP-1 pathways are involved in reward processing for multiple substances. But Kahn emphasizes that randomized controlled trials are still underway, and we should be careful about overclaiming. He also discusses early explorations in Alzheimer's disease, liver disease, and even polycystic ovary syndrome.

Nova: : It's remarkable. A drug class that started as a diabetes treatment is revealing itself to be relevant to multiple disease processes. Kahn must see this as a paradigm shift.

Nova: He calls it a hinge moment in metabolic medicine. His prediction, which he supports with interviews with leading researchers, is that we're moving toward an era where these medications might be prescribed based on broader metabolic health profiles rather than narrow BMI or diabetes criteria alone. But he's also careful to note that we need long-term safety data, and we need to be thoughtful about medicalizing weight in ways that could have unintended social consequences.

Nova: So as we wrap up, let's take stock of what Jeremy Kahn's The Ultimate Guide to the New GLP-1 Medications for Weight Loss and Diabetes leaves us with. First, these are genuinely remarkable medications. They work by amplifying a natural hormone system that regulates appetite, blood sugar, and metabolism. The dual agonists like tirzepatide are pushing weight loss into territory once reserved for surgery. And the systemic benefits — cardiovascular protection, kidney preservation, possibly more — are reshaping our understanding of metabolic disease.

Nova: : But the flip side is equally important. These are not quick fixes. Side effects are real, though manageable for most people. The weight comes back if you stop taking them. Muscle loss is a genuine concern without proper nutrition and exercise. And the cost is prohibitive for millions who could benefit.

Nova: Kahn's book is ultimately a call for informed decision-making. He wants patients and providers to go in with eyes wide open — understanding the science, the trade-offs, and the commitment involved. He also pushes readers to think about the bigger picture: if we've developed drugs that can dramatically improve metabolic health but we can't get them to the people who need them most, what does that say about our healthcare system?

Nova: : That's the question that sticks with me. The science has delivered something extraordinary. Now the question is whether our policies, our pricing, and our priorities will rise to meet the moment.

Nova: Beautifully put. And on that note, we'll leave you with one final thought from Kahn's book: these medications don't replace healthy eating and physical activity — they make those behaviors biologically easier to sustain. They're not a shortcut. They're a tool. And like any powerful tool, they require respect, knowledge, and responsible use.

Nova: : This is Aibrary. Congratulations on your growth!

Nova: Thanks for listening, and we'll see you next time.